InsiderTrades

Form 4 for IMDX Insight Molecular Diagnostics Inc.

Accepted 2022-08-17 00:00:00 ET · period of report 2022-08-15 · accession 0001493152-22-023380 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
D 2022-08-17 2022-08-15 IMDX Gutfreund John Peter Dir A - Grant $0.00 +10.0K 10.0K New $0
DI 2022-08-17 2022-08-15 IMDX Gutfreund John Peter Dir P - Purchase $0.93 +25.0K 25.0K New +$23.2K
D 2022-08-17 2022-08-15 IMDX Gutfreund John Peter Dir A - Grant $0.00 +45.0K 45.0K New $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock, no par value 2022-08-15 A A 10,000 $0.00 10,000 D See footnote — — (F1) The Restricted Stock Units shall vest one year from the date of grant, subject to the Reporting Person's continued service as a director of the Issuer from the date of grant until the vesting date or, if earlier, until the next annual meeting of shareholders. (F3) These securities are held by the minor children of the Reporting Person, and the Reporting Person has voting and dispositive control over such securities.
2 Common Common Stock, no par value 2022-08-15 P A 25,000 $0.93 25,000 I — — (F2) The price of $0.93 per share represents a weighted average of prices ranging from $0.91 to $0.97 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
3 Derivative Option to Purchase Common Stock 2022-08-15 A A 45,000 $0.00 45,000 D $0.97 · — to 2032-08-15 45,000 Common Stock (F4) Options shall vest one year from the date of grant, subject to the Reporting Person's continued service as a director of the Issuer from the date of grant until the vesting date or, if earlier, until the next annual meeting of shareholders.